Barrett’s Esophagus

Dr. Pleskow’s major research interests have been the study of serologic markers in pancreatic disease, therapeutic pancreaticobiliary endoscopy and endoscopic ultrasound. He pioneered the endoscopic placement of gold markers in patients with pancreaticobiliary malignancy to facilitate Cyberknife therapy. He and his colleagues have worked closely on the endoscopic treatment of Gastroesophageal Reflux Disease (GERD) and Barrett’s esophagus. Dr. Pleskow is also an active and influential member of the NPF (National Pancreas Foundation) board and its Executive Committee. He has also previously served as Executive Director and currently presides over the Scientific Advisory Committee and sits on the Grant Review Council. Dr. Pleskow holds board certification from the American Board of Internal Medicine (Gastroenterology). Dr. Erim is currently the Director of Endoscopy at Cleveland Clinic Florida. His major clinical interests are Barrett's esophagus, minimally invasive mucosal resection techniques, therapeutic pancreaticobiliary endoscopy and endoscopic ultrasound.

Chapter 1. A disease entity is identifiedChapter 2. Fluctuating risk factors and epidemiologyChapter 3. Metaplasia and dysplasia in Barrett’s esophagusChapter 4. Genetics of Barrett’s and Esophageal Adenocarcinoma: implications for prevention, diagnosis and treatment Chapter 5. Biomarkers in Barrett’s and Esophageal AdenocarcinomaChapter 6. Diagnosis of Barrett’s esophagusChapter 7. Screening and surveillance of Barrett’s esophagusChapter 8. Enhanced Imaging of the Esophagus: Spectroscopy Chapter 9. Enhanced Imaging of the Esophagus : Optical Coherence Tomography Chapter 10. Enhanced Imaging of the Esophagus : Confocal Laser Endomicroscopy Chapter 11. History of ablative therapies for Barrett’s and superficial adenocarcinoma Chapter 12. Radiofrequency ablation Chapter 13. Cryospray ablationChapter 14. Endoscopic surgical therapiesChapter 15. Chemoprevention of Barrett’s and AdenocarcinomaChapter 16. Post treatment surveillance, risk for recurrence of Barrett’s and adenocarcinoma after treatment